keyword
MENU ▼
Read by QxMD icon Read
search

Montelukast allergic rhinitis

keyword
https://www.readbyqxmd.com/read/27826703/leukotriene-receptor-antagonists-and-antiallergy-drugs
#1
Tsutomu Tamada, Masakazu Ichinose
As one of the candidates of the therapeutic strategy for asthma in addition to inhaled corticosteroids (ICS), leukotriene receptor antagonists (LTRAs) are known to be useful for long-term management of asthma patients complicated by allergic rhinitis (AR) or exercise-induced asthma (EIA). Currently available LTRAs are pranlukast hydrate, zafirlukast, and montelukast. These LTRAs have a bronchodilator action and inhibit airway inflammation, resulting in a significant improvement of asthma symptoms, respiratory function, inhalation frequency of as-needed inhaled β2-agonist, airway inflammation, airway hyperresponsiveness, dosage of ICSs, asthma exacerbations, and patients' QOL...
November 9, 2016: Handbook of Experimental Pharmacology
https://www.readbyqxmd.com/read/27785374/montelukast-in-the-treatment-of-perennial-allergic-rhinitis-in-paediatric-japanese-patients-an-open-label-clinical-trial
#2
Kimihiro Okubo, Yoichi Inoue, Hirotaka Numaguchi, Kumi Tanaka, Itori Saito, Nobuyuki Oshima, Yuki Matsumoto, Marita Prohn, Anish Mehta, Chisato Nishida, George Philip
Background: This study was conducted to evaluate the safety and tolerability, and population pharmacokinetics (PPK) of montelukast as well as efficacy in the treatment of perennial allergic rhinitis (PAR) in paediatric Japanese patients aged between 1 and 15 years. Methods: In this multi-centre, open-label trial, 87 paediatric Japanese patients with PAR received montelukast 4 mg oral granules (OG) for 4 weeks (1-5-year-olds, N = 15), 4 mg OG for 12 weeks (1-5-year-olds, N = 36), 5 mg chewable tablets (CT) for 12 weeks (6-9-year-olds, N = 18), or 5 mg CT for12 weeks (10-15-year-olds, N = 18)...
2016: Journal of drug assessment
https://www.readbyqxmd.com/read/27764975/early-patient-experiences-with-montelukast-orally-disintegrating-tablets-in-japan-a-cross-sectional-survey-of-treatment-satisfaction-in-patients-with-asthma-and-or-allergic-rhinitis
#3
Diane Whalley, Tanaz Petigara, Lawrence Rasouliyan, Keisuke Tobe, Kaan Tunceli
OBJECTIVE: Orally disintegrating tablets (ODTs) offer a valuable treatment option, particularly when swallowing solid tablets with water is difficult or inconvenient. Montelukast is an effective treatment for asthma and allergic rhinitis (AR), and an ODT formulation became available in Japan in 2015. This study investigated levels of satisfaction with this new formulation among adults with asthma and/or AR in Japan. METHODS: Patients aged 20 years or older who were refilling a prescription for montelukast ODT in pharmacies across Japan completed questions on satisfaction with key features of montelukast ODT and the 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9)...
October 21, 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/27527264/treatment-effect-of-sublingual-immunotherapy-tablets-and-pharmacotherapies-for-seasonal-and-perennial-allergic-rhinitis-pooled-analyses
#4
Stephen R Durham, Peter S Creticos, Harold S Nelson, Ziliang Li, Amarjot Kaur, Eli O Meltzer, Hendrik Nolte
BACKGROUND: Data comparing the treatment effect of allergy immunotherapy and pharmacotherapy are lacking. OBJECTIVE: We sought to indirectly compare the treatment effect of sublingual immunotherapy (SLIT)-tablets with pharmacotherapy for seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR). METHODS: Pooled data from randomized, double-blind, placebo-controlled trials for the clinical development programs of selected allergic rhinitis treatments were evaluated...
October 2016: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/27522261/the-efficacy-and-safety-of-h1-antihistamine-versus-montelukast-for-allergic-rhinitis-a-systematic-review-and-meta-analysis
#5
Chunhui Wei
PURPOSE: In order to verify the differences of effectiveness and safety between SAHs and Montelukast, and to find out potential uncared-for problems, we performed a systematic review and Meta-analysis to proceed a qualitative describe and quantitative assessment. METHODS: We searched the databases of Pubmed, the Cochrane Library, Nature and Science as well as Wanfang data and CNKI from 2000 to March 2016, using key words "Montelukast SAH" or "H1-antihistamine Montelukast", or "Loratadine Montelukast", or "Desloratadine Montelukast", or "Levocetirizine Montelukast", or "Cetirizen Montelukast", or "Fexofenadine Montelukast"...
October 2016: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/27485393/montelukast-current-indications-and-prospective-future-applications
#6
Naim Kittana, Suhaib Hattab, Azza Ziyadeh-Isleem, Nidal Jaradat, Abdel-Naser Zaid
INTRODUCTION: Montelukast is recommended for the treatment of asthma, exercise -induced bronchospasm and allergic rhinitis. Several trials demonstrated potential therapeutic effects in other respiratory conditions, and different animal-model-based studies explored potential pharmacological actions in non-respiratory conditions. AREAS COVERED: Clinical investigations on the pharmacotherapeutic effects of montelukast, in addition to in-vivo studies on animal models of non-respiratory diseases...
September 2016: Expert Review of Respiratory Medicine
https://www.readbyqxmd.com/read/27152482/predictors-of-asthma-following-severe-respiratory-syncytial-virus-rsv-bronchiolitis-in-early-childhood
#7
Susan Lu, Tina V Hartert, Mark L Everard, Hilde Giezek, Linda Nelsen, Anish Mehta, Hima Patel, Barbara Knorr, Theodore F Reiss
BACKGROUND: We sought to identify predictors of asthma development following severe early childhood RSV bronchiolitis. Different definitions of asthma were also compared. METHODS: This longitudinal, observational study (N = 343) followed patients (<2 years old) from a placebo-controlled trial (N = 979) of montelukast after RSV bronchiolitis to identify clinical, demographic, or biochemical predictors of asthma, atopic disorders, and chronic asthma therapy use at 6 years of age (Clinical Trials Registry Number: NCT01140048)...
December 2016: Pediatric Pulmonology
https://www.readbyqxmd.com/read/27101674/-clinical-evaluation-of-montelukast-plus-budesonide-nasal-spray-and-desloratadine-citrate-disodium-in-treating-moderate-and-severe-persistent-allergic-rhinitis
#8
RANDOMIZED CONTROLLED TRIAL
Renzia Wang, Chunhui Zhang
OBJECTIVE: To investigate the clinical efficacy of montelukast plus budesonide nasal spray and desloratadine citrate disodium tablets on moderate and severe persistent allergic rhinitis. METHOD: Senenty patients with moderate and severe persistent allergic rhinitis were devided randomly study group (n = 35) and control group (n = 35). The study group were treated with montelukast sodium tablets combined with budesonide nasal spray and desloratadine citrate disodium tablets for 4 weeks, the control group received budesonide nasal spray and desloratadine citrate disodium tablets for 4 weeks...
December 2015: Journal of Clinical Otorhinolaryngology, Head, and Neck Surgery
https://www.readbyqxmd.com/read/27084419/minimal-clinically-important-difference-mcid-in-allergic-rhinitis-agency-for-healthcare-research-and-quality-or-anchor-based-thresholds
#9
Eli O Meltzer, Dana Wallace, Mark Dykewicz, Lucy Shneyer
BACKGROUND: In 2013, the Agency for Healthcare Research and Quality (AHRQ) recommended that allergic rhinitis (AR) studies calculate a minimal clinically important difference (MCID) based on an estimated threshold equal to 30% of the maximum total nasal symptom score. Applying this threshold, their data showed no differences between well-established treatments, and a subsequent analysis using prescribing information found no differences between active treatments and placebo controls. OBJECTIVE: The objective of this study was to demonstrate the application of an evidence-based model to determine MCIDs for AR studies, with an absolute value for an anchor-based threshold and validated methods for calculating distribution-based thresholds...
July 2016: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/26922938/a-case-of-pranlukast-induced-anaphylactic-shock
#10
Sujeong Kim, Jong Myung Lee
Leukotriene receptor antagonists, which are generally considered safe with a few adverse drug reactions, are increasingly used in the treatment of various allergic diseases, including asthma and allergic rhinitis. Although a few anaphylactic reactions to montelukast have been reported worldwide, there is still a lack of reports about severe adverse drug reactions associated with pranlukast. Here, we report a case of severe hypersensitivity reaction associated with pranlukast. A 65-year-old woman developed anaphylactic shock that presented as generalized urticaria, angioedema, collapse, and loss of consciousness after receiving pranlukast...
May 2016: Allergy, Asthma & Immunology Research
https://www.readbyqxmd.com/read/26834076/effectiveness-of-leukotriene-receptor-antagonism-in-the-postoperative-management-of-chronic-rhinosinusitis
#11
Joshua C Yelverton, Thomas W Holmes, Christopher M Johnson, Camilo Reyes Gelves, Stilianos E Kountakis
BACKGROUND: Montelukast is used in the treatment of allergic rhinitis and asthma. It has been used as adjuvant therapy in patients with chronic rhinosinusitis (CRS), but its effectiveness has not been evaluated. This study evaluates the efficacy of adjuvant leukotriene receptor antagonism in CRS and subtypes. METHODS: Retrospective review of collected data at a tertiary-referral institution. We identified all patients who were prescribed montelukast postoperatively and had a lapse in therapy for at least 1 month (n = 50), so that the patients themselves serve as their own control group...
March 2016: International Forum of Allergy & Rhinology
https://www.readbyqxmd.com/read/26451086/investigation-of-the-bioequivalence-of-montelukast-chewable-tablets-after-a-single-oral-administration-using-a-validated-lc-ms-ms-method
#12
RANDOMIZED CONTROLLED TRIAL
Abdel Naser Zaid, Murad N Abualhasan, David G Watson, Ayman Mousa, Nadia Ghazal, Rana Bustami
BACKGROUND: Montelukast (MT) is a leukotriene D4 antagonist. It is an effective and safe medicine for the prophylaxis and treatment of chronic asthma. It is also used to prevent acute exercise-induced bronchoconstriction and as a symptomatic relief of seasonal allergic rhinitis and perennial allergic rhinitis. OBJECTIVE: The aim of this study was to evaluate the bioequivalence (BE) of two drug products: generic MT 5 mg chewable tablets versus the branded drug Singulair(®) pediatric 5 mg chewable tablets among Mediterranean volunteers...
2015: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/26385352/antileukotrienes-in-upper-airway-inflammatory-diseases
#13
REVIEW
Cemal Cingi, Nuray Bayar Muluk, Kagan Ipci, Ethem Şahin
Leukotrienes (LTs) are a family of inflammatory mediators including LTA4, LTB4, LTC4, LTD4, and LTE4. By competitive binding to the cysteinyl LT1 (CysLT1) receptor, LT receptor antagonist drugs, such as montelukast, zafirlukast, and pranlukast, block the effects of CysLTs, improving the symptoms of some chronic respiratory diseases, particularly bronchial asthma and allergic rhinitis. We reviewed the efficacy of antileukotrienes in upper airway inflammatory diseases. An update on the use of antileukotrienes in upper airway diseases in children and adults is presented with a detailed literature survey...
November 2015: Current Allergy and Asthma Reports
https://www.readbyqxmd.com/read/26012287/-recent-advances-in-allergic-rhinitis
#14
REVIEW
Meijun Liang, Rui Xu, Geng Xu
Allergic rhinitis (AR) clinically expressed by sneezing, rhinorrhea, nasal itching and congestion is an allergen-driven mucosal inflammatory disease which is modulated by immunoglobulin E. Epidemiological studies have indicated that prevalence of AR continues to increase, and it has been a worldwide health problem that places a significant healthcare burden on individuals and society. Given the evolving understanding of the process by which an allergen is recognized and the roles of mediators which account for AR progress, the pathogenesis of AR has become clearer...
February 2015: Journal of Clinical Otorhinolaryngology, Head, and Neck Surgery
https://www.readbyqxmd.com/read/25868617/antiallergic-effect-of-piperine-on-ovalbumin-induced-allergic-rhinitis-in-mice
#15
COMPARATIVE STUDY
Urmila Aswar, Sumit Shintre, Shilpa Chepurwar, Manoj Aswar
CONTEXT: Allergic rhinitis (AR) is a global health problem that affects a large number of population. Piperine (PIP) has been reported to exhibit anti-inflammatory, anti-histaminic, and immunomodulatory activities; however, its antiallergic profile has not been studied. OBJECTIVE: The objective of the study was to investigate the antiallergic potential of PIP in ova-albumin (OVA)-induced AR, mast cell degranulation (MSD), and OVA-induced paw edema. MATERIALS AND METHODS: Mice were sensitized with OVA alternately on 1, 3, 5, 7, 9, 11, and 13th day...
2015: Pharmaceutical Biology
https://www.readbyqxmd.com/read/25867532/a-network-meta-analysis-of-randomized-controlled-trials-focusing-on-different-allergic-rhinitis-medications
#16
Juan Xiao, Wen-Xu Wu, Yuan-Yuan Ye, Wen-Jun Lin, Lu Wang
This study is aimed to investigate the effectiveness of 4 allergic rhinitis (AR) drugs (loratadine, cetirizine, montelukast, and desloratadine) in reducing functional problems in patients, as indicated by rhinoconjunctivitis quality of life questionnaire scores. After an exhaustive search of electronic databases containing published scientific literature, high-quality randomized controlled trials relevant to our study were selected based on a stringent predefined inclusion and exclusion criteria. Statistical analyses were conducted using STATA 12...
November 2016: American Journal of Therapeutics
https://www.readbyqxmd.com/read/25595597/a-long-standing-mystery-solved-the-formation-of-3-hydroxydesloratadine-is-catalyzed-by-cyp2c8-but-prior-glucuronidation-of-desloratadine-by-udp-glucuronosyltransferase-2b10-is-an-obligatory-requirement
#17
Faraz Kazmi, Joanna E Barbara, Phyllis Yerino, Andrew Parkinson
Desloratadine (Clarinex), the major active metabolite of loratadine (Claritin), is a nonsedating long-lasting antihistamine that is widely used for the treatment of allergic rhinitis and chronic idiopathic urticaria. For over 20 years, it has remained a mystery as to which enzymes are responsible for the formation of 3-hydroxydesloratadine, the major active human metabolite, largely due to the inability of any in vitro system tested thus far to generate this metabolite. In this study, we demonstrated that cryopreserved human hepatocytes (CHHs) form 3-hydroxydesloratadine and its corresponding O-glucuronide...
April 2015: Drug Metabolism and Disposition: the Biological Fate of Chemicals
https://www.readbyqxmd.com/read/25351124/-meta-analysis-of-leukotriene-receptor-antagonist-montelukast-in-the-treatment-of-allergic-rhinitis
#18
Yi Lu, Min Yin, Lei Cheng
OBJECTIVE: To evaluate the treatment outcomes of leukotriene receptor antagonists (LTRA) as monotherapy or combined with the second-generation oral H1-histamines in the treatment of allergic rhinitis (AR), and to provide a basis for optimizing clinical therapeutic strategies. METHODS: PubMed,EMBASE, CBMdisc and CJFD databases, retrieving randomized controlled trials (RCTs) of AR therapy literatures were searched. Based on the literature inclusion and exclusion criteria, the related literatures were selected and the quality was evaluated by using the Jadad scale...
August 2014: Zhonghua Er Bi Yan Hou Tou Jing Wai Ke za Zhi, Chinese Journal of Otorhinolaryngology Head and Neck Surgery
https://www.readbyqxmd.com/read/25330633/-the-relevance-of-leukotriene-d4-synthase-gene-a-444-c-polymorphism-to-clinical-responsiveness-of-leukotriene-receptor-antagonist-in-patients-with-allergic-rhinitis
#19
Xiaoling Liu, Hong Luo, Jianbin Zhang, Nengbing Yan, Ji Li, Ye Yu, Jun Liu, Yan Jiang, Pengju Wang
OBJECTIVE: To investigate the leukotriene D4 synthase gene A (LTD4S A)-444 C polymorphism in persistent allergic rhinitis (AR) of Chinese Han nationality and to evaluate its relevance to clinical responsiveness of leukotriene receptor antagonist. METHOD: There were 150 patients [87 males, 63 females, average age (38 +/- 14)] diagnosed with persistent AR in Allergy clinic in our hospital from March 2010 to March 2012; 146 healthy controls (78 males, 68 females, mean age (39 +/- 12))...
July 2014: Journal of Clinical Otorhinolaryngology, Head, and Neck Surgery
https://www.readbyqxmd.com/read/25250173/bioequivalence-of-two-formulations-of-montelukast-sodium-4-mg-oral-granules-in-healthy-adults
#20
Constanze Fey, Ursula Thyroff-Friesinger, Spencer Jones
Montelukast is an effective and well-tolerated treatment for the prophylaxis and chronic treatment of asthma, acute prevention of exercise-induced bronchoconstriction and symptomatic relief of seasonal allergic rhinitis and perennial allergic rhinitis. The aim of the study was to compare bioavailability, and characterise the pharmacokinetic profile and safety of Sandoz generic montelukast 4 mg oral granules relative to Singulair(®) mini (Merck, Sharp & Dohme). An open-label, randomised, single-dose, two-treatment, two-period, two-sequence, two-way crossover bioequivalence study was conducted in healthy male volunteers aged 18-55 years, under fasting conditions...
2014: Clinical and Translational Allergy
keyword
keyword
33627
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"